Authors

Latest:

Dr. Tiacci on Vemurafenib and Rituximab Combo in Hairy Cell Leukemia

Enrico Tiacci, MD, discusses updated data of a phase II trial investigating the combination of vemurafenib and rituximab for patients with relapsed/refractory hairy cell leukemia.

Enrique Grande, MD

Latest:

Dr. Grande on the Rationale of the IMvigor130 Trial in Urothelial Cancer

Enrique Grande, MD, discusses the rationale of the IMvigor130 trial in urothelial cancer.

Enrique Soto Perez de Celis, MD, MSc

Latest:

Dr. Soto Perez de Celis on COVID-19 Risk Reduction

Enrique Soto Pérez de Celis, MD, MSc, a geriatric oncologist and researcher in the Department of Geriatrics at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City, Mexico, discusses ways to reduce the risk of contracting the novel coronavirus 2019 (COVID-19).

Enriqueta Felip, MD

Latest:

Dr. Felip on Immunotherapy Alone or in Combination in Lung Cancer

Enriqueta Felip, MD, discusses immunotherapy alone versus immunotherapy plus chemotherapy in patients with lung cancer.

Enriqueta Felip, MD, PhD

Latest:

Dr. Felip Discusses Ceritinib's Response in ALK+ NSCLC

Enriqueta Felip, MD, PhD, medical oncologist, Vall d'Hebron University Hospital, Barcelona, Spain, discusses the efficacy and safety of ceritinib in patients with ALK-positive non-small cell lung cancer (NSCLC).

Enriqueta Felip, MD, PhD, Vall d’Hebron University Hospital

Er Chen, MPP

Latest:

Cost-Effectiveness of 70-Gene MammaPrint Signature in Node-Negative Breast Cancer

Breast cancers with similar clinicopathologic characteristics may have strikingly different outcomes.

Eric A. Collisson, MD

Latest:

Dr. Collisson on the Difficulty of Diagnosing Cholangiocarcinoma

Eric A. Collisson, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the difficulty of diagnosing cholangiocarinoma.

Eric A. Jonasch, MD, MD Anderson Cancer Center

Latest:

Second-Line Treatment Armamentarium in Clear Cell RCC

Comprehensive insight to treatment options available in the second-line setting of advanced clear cell renal cell carcinoma.

Eric A. Klein, MD

Latest:

Dr. Klein on the Safety of VERU-111 in mCRPC

Eric Klein, MD, discusses safety data with VERU-111 from a phase 2 trial that enrolled patients with metastatic castration-resistant prostate cancer that was presented during the 2021 Genitourinary Cancers Symposium.

Eric B. Durbin, DrPH, MS

Latest:

Kentucky Taps Into Data Repositories for an Attack on its Extraordinary Cancer Burden

Open access to unbiased data repositories of molecular and clinical data will be essential to accelerating future discoveries in precision medicine.

Eric H. Liu, MD, FACS, Rocky Mountain Cancer Center

Eric Haura, MD

Latest:

Dr. Eric Haura on New Biomarker Assay System for Lung Cancer

Eric Haura, MD, senior member, Moffitt Cancer Center, discusses new approaches to identifying bypass signaling mechanisms and biomarkers in lung cancer.

Eric J. Jacobs, PhD

Latest:

Association Between BMI and Pancreatic Cancer Mortality

Eric J. Jacobs, PhD, cancer epidemiologist and strategic director of pharmacoepidemiology, American Cancer Society, discusses results from a prospective cohort study examining the association between BMI and pancreatic cancer mortality.

Eric J. Sherman, MD

Latest:

Dr. Sherman on Selumetinib-Enhanced Radioiodine Uptake

Eric J. Sherman, MD, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses a pilot study of selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.

Eric J. Sherman, MD, Memorial Sloan Kettering Cancer Center

Eric J. Sherman, MD, MSKCC

Eric Jonasch, MD

Latest:

Dr Jonasch on the Preliminary Efficacy of NKT-2152 in Advanced ccRCC

Eric Jonasch, MD, discusses preliminary findings from a trial investigating NKT-2152 in previously treated advanced clear cell renal cell carcinoma.

Eric Jonasch, MD, MD Ande

Eric Jonasch, MD, MD Anders